AAV gene therapy for GBA-PD and Gaucher Disease

Mutations inGBA1, the gene encoding glucocerebrosidase (GCase), are the most common risk factor for Parkinson’s Disease (PD). GBA-PD patients are a well-defined genetic subpopulation of PD carrying heterozygous mutations inGBA1. Additionally, bi-allelic mutations inGBA1cause Gaucher Disease (GD), a lysosomal storage disorder. Reduction or loss of GCase activity, a lysosomal enzyme leads to the accumulation of lipid substrates within lysosomes, disrupting lipid homeostasis and promoting cellular toxicity. Here, we report an AAV-mediatedGBA1replacement strategy to treat GD and GBA-PD by a one-time infusion via intravenous (GD Type 1) or intra-CSF (GBA-PD) route of administration. We engineered human GCase to be readily secretable to facilitate cross-correction across tissues. We developed CBE (conduritol ß- epoxide) induced lipid accumulation models both in mice and non-human primates (NHPs) to assess efficacy of our engineered constructs. Based on data across both species, we nominated AAV.GMU01 SS3-GBA1 as our lead candidate. SS3-GBA1 is robustly secreted, cross-corrects across cell types in the brain and promotes lipid clearance. By comparing human GCase levels in AAV-treated NHP brains to healthy human donor brain, we demonstrate that AAV.GMU01 SS3-GBA1 replenishes the GCase deficit seen in GBA-PD patients, thus, restoring GCase to near-physiological levels. Furthermore, intravenous dosing of SS3-GBA1 promotes lipid clearance across liver, spleen, bone marrow and muscle, key target tissues in GD Type 1. Importantly, AAV.GMU01 SS3-GBA1 is well-tolerated with no adverse findings. Collectively, our data establish a therapeutic strategy for the treatment of Gaucher Disease and GBA-associated Parkinson’s Disease with a single gene therapy product.